Lilly cuts prices for some insulin products; a CRISPR patent fight redux with new gene editing tools

Taking stock of the drug industry, from the lab to the medicine chest

March 1, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Reed Saxon/AP Eli Lilly cuts prices for some insulin products, but some are wary David Ricks, Eli Lilly's chairman and CEO, presented the moves as the latest bid by the company to work within a broken system. By Matthew Herper and Ed Silverman STAT+ | CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools The ultimate winner might not be who invented the gene editing technology, but whoever uses it to make the best drug the fastest. By Jason Mast and Allison DeAngelis and Megan Molteni STAT+ | FDA approves Reata's treatment for rare neurological disease The FDA's approval decision settles a closely followed drug review that had flummoxed investors trying to predict the outcome. By Adam Feuerstein Rebecca Blackwell/AP Covid-19 surveillance added new burdens on essential workers — and gave them little data to protect their health Covid-19 surveillance technologies added new burdens on essential workers — and gave them little data to protect their health. By Ambar Castillo

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser